HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,873-1,884 of 4,505
Drug study icon
CompletedEUCTR 2020-000094-24

A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Bulgaria
SchizophreniaHistorical research record
Countries
Bulgaria, Croatia, Latvia, + 1 other
Sponsor
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Drug study icon
CompletedEUCTR 2007-003820-40

A Phase 3 Randomized, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Lithuania
SchizophreniaHistorical research record
Countries
Lithuania
Sponsor
Dainippon Sumitomo Pharma America, Inc.
Drug study icon
CompletedEUCTR 2011-002513-11

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed dose OPC-34712 (4, 2, and 1 mg/day) in the Treatment of Adults With Acute Schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Slovakia
SchizophreniaHistorical research record
Countries
Slovakia
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedEUCTR 2011-002538-38

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Latvia
SchizophreniaHistorical research record
Countries
Latvia, Poland
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.